Aquestive Therapeutics (NASDAQ:AQST – Free Report) had its price target upped by HC Wainwright from $9.00 to $10.00 in a report released on Monday morning, Benzinga reports. The firm currently has a buy rating on the stock.
Separately, JMP Securities restated a market outperform rating and set a $9.00 price target on shares of Aquestive Therapeutics in a research report on Monday, August 12th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Aquestive Therapeutics currently has a consensus rating of Buy and an average price target of $8.67.
Get Our Latest Stock Analysis on Aquestive Therapeutics
Aquestive Therapeutics Trading Down 2.3 %
Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.08. The company had revenue of $20.10 million during the quarter, compared to the consensus estimate of $12.62 million. During the same quarter in the prior year, the company posted ($0.10) earnings per share. Sell-side analysts forecast that Aquestive Therapeutics will post -0.47 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of AQST. Vanguard Group Inc. boosted its position in Aquestive Therapeutics by 71.7% in the 1st quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company’s stock valued at $13,813,000 after buying an additional 1,353,518 shares during the last quarter. Janney Montgomery Scott LLC acquired a new position in shares of Aquestive Therapeutics in the 1st quarter valued at $1,456,000. Blue Owl Capital Holdings LP lifted its stake in shares of Aquestive Therapeutics by 30.3% in the 2nd quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company’s stock valued at $2,964,000 after purchasing an additional 265,000 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of Aquestive Therapeutics in the 2nd quarter valued at $594,000. Finally, Deerfield Management Company L.P. Series C acquired a new position in shares of Aquestive Therapeutics in the 2nd quarter valued at $380,000. 32.45% of the stock is currently owned by institutional investors.
Aquestive Therapeutics Company Profile
Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
Further Reading
- Five stocks we like better than Aquestive Therapeutics
- How to Most Effectively Use the MarketBeat Earnings Screener
- When Is the Best Time to Invest in Mutual Funds?
- Best Stocks Under $10.00
- Is NVIDIA Stock in a Correction or Consolidation?
- 3 Tickers Leading a Meme Stock Revival
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.